Ascentage Pharma Group Corp Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Ascentage Pharma Group Corp Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10515
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ascentage Pharma Group Corp Ltd (Ascentage Pharma) is a biopharmaceutical company that discovers and develops targeted small-molecule therapeutics for the treatment of cancers, hepatitis B and age-related diseases. The company’s pipeline product includes apoptosis compounds and kinase inhibitors such as APG-1387, APG-1252, APG-115, APG-2575, APG-8361, APG-1351, and APG-2449. Ascentage Pharma provides services including medicinal chemistry, analytical and formulation pharmaceutical sciences, process development, biological sciences, regulatory and compliance, preclinical studies and clinical development. The company operates through research and development centers and production facilities in Hong Kong, China, the US. Ascentage Pharma is headquartered in Pudong, China.

Ascentage Pharma Group Corp Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ascentage Pharma Group Corp Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ascentage Pharma Group Corp Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ascentage Pharma Group Corp Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ascentage Pharma Group Corp Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ascentage Pharma Group Corp Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ascentage Pharma Group Corp Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Ascentage Pharma Raises USD150 Million in Series C Financing 10
Ascentage Pharma Raises USD72 Million in Series B Financing 11
Ascentage Pharma Raises USD15.5 Million in Series A Financing 12
Partnerships 13
Ascentage Pharma Enters Agreement with Unity Biotechnology 13
3SBio Enters Into Strategic Alliance with Ascentage Pharma 14
Licensing Agreements 15
Ascentage Pharma Enters into Licensing Agreement with Merck 15
Ascentage Pharma Amends Licensing Agreement with Regents of the University of Michigan 16
Equity Offering 17
Ascentage Pharma Files for USD300 Million IPO 17
Ascentage Pharma Group Corp Ltd – Key Competitors 18
Ascentage Pharma Group Corp Ltd – Key Employees 19
Ascentage Pharma Group Corp Ltd – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Corporate Communications 21
Jan 03, 2018: Ascentage Pharma Announces Formation of Clinical Advisory Board 21
Sep 25, 2017: Ascentage Pharma: Yingjie (Jason) Huang, M.D., to Join Ascentage Pharma as Senior Vice President of Clinical Development 23
Jul 05, 2017: Ascentage Pharma Announces Appointment of Han Li as Chief Financial Officer 24
Product News 25
06/26/2017: Ascentage Announces CFDA Grants Bcl-2/Bcl-XL inhibitor APG-1252 IND Approval for Treatment of Cancers 25
Product Approvals 26
Jan 08, 2018: Ascentage Pharma Announces Acceptance of IND Application by China FDA for Clinical Study of Novel IAP Inhibitor to Treat Hepatitis B Infection 26
Nov 15, 2017: Ascentage Pharma Announces U.S. FDA Acceptance of IND Application for Clinical Study of Novel IAP Inhibitor APG-1387 to Treat Advanced Solid Tumors and Blood Cancers 27
Clinical Trials 28
May 21, 2018: Ascentage Pharma Announces Promising Phase 1 Interim Results Of APG-1252 At 2018 ASCO Annual Meeting 28
May 21, 2018: Ascentage Pharma Announces Promising Phase 1 Interim Results Of APG-1387 At 2018 ASCO Annual Meeting 29
Feb 21, 2018: Ascentage Pharma to Present at the IASLC 18th Lung Cancer Targeted Therapies Meeting 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Ascentage Pharma Group Corp Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Ascentage Pharma Group Corp Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ascentage Pharma Group Corp Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ascentage Pharma Group Corp Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ascentage Pharma Group Corp Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Ascentage Pharma Group Corp Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ascentage Pharma Raises USD150 Million in Series C Financing 10
Ascentage Pharma Raises USD72 Million in Series B Financing 11
Ascentage Pharma Raises USD15.5 Million in Series A Financing 12
Ascentage Pharma Enters Agreement with Unity Biotechnology 13
3SBio Enters Into Strategic Alliance with Ascentage Pharma 14
Ascentage Pharma Enters into Licensing Agreement with Merck 15
Ascentage Pharma Amends Licensing Agreement with Regents of the University of Michigan 16
Ascentage Pharma Files for USD300 Million IPO 17
Ascentage Pharma Group Corp Ltd, Key Competitors 18
Ascentage Pharma Group Corp Ltd, Key Employees 19
Ascentage Pharma Group Corp Ltd, Other Locations 20

List of Figures
Ascentage Pharma Group Corp Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ascentage Pharma Group Corp Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ascentage Pharma Group Corp Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ascentage Pharma Group Corp Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ascentage Pharma Group Corp Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ascentage Pharma Group Corp Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Ascentage Pharma Group Corp Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ascentage Pharma Group Corp Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Ascentage Pharma Group Corp Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Geron Corp (GERN):製薬・医療:M&Aディール及び事業提携情報
    Summary Geron Corp (Geron) is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor as a potential treatment for cancer. The company is evaluating its flagship product candidate Imetelstat in two clinical trials: IMbark and IMerge in partnership with Janssen Biotech, Inc. …
  • Fountain Biopharma Inc (4159):製薬・医療:M&Aディール及び事業提携情報
    Summary Fountain Biopharma Inc (Fountain Biopharma), a subsidiary of Microbio Co Ltd, is a developer of therapeutic monoclonal antibodies and DNA aptamers. The company’s technologies include IgE development platform, IEA’s drug development platform and tumor stem cell culture platform. Its IgE devel …
  • Lanka IOC PLC (LIOC.N0000):企業の財務・戦略的SWOT分析
    Summary Lanka IOC Plc (LIOC), a subsidiary of Indian Oil Corporation Ltd is an oil and gas company that imports, sells and distributes petroleum products. The company's products include lubricants, fuels, bitumen and bunkering products. It provides automotive lubricants, including passenger car, die …
  • Voltalia SA (VLTSA):企業の財務・戦略的SWOT分析
    Voltalia SA (VLTSA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Blue Cross and Blue Shield Association:企業の戦略的SWOT分析
    Blue Cross and Blue Shield Association - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • SRI International:企業のM&A・事業提携・投資動向
    SRI International - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SRI International Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Analog Devices Inc (ADI):企業の財務・戦略的SWOT分析
    Analog Devices Inc (ADI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Almac Discovery Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Almac Discovery Ltd (Almac Discovery), a subsidiary of Almac Group Ltd is a healthcare service provider that discovers and develops drugs for the treatment of cancer. The company develops drugs, small molecule and therapeutic peptide, biomarkers and diagnostic tools. It provides early drug d …
  • ALK-Abello AS (ALK B):企業の財務・戦略的SWOT分析
    ALK-Abello AS (ALK B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Banco di Desio e della Brianza SpA:企業の戦略・SWOT・財務分析
    Banco di Desio e della Brianza SpA - Strategy, SWOT and Corporate Finance Report Summary Banco di Desio e della Brianza SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Advanced Biological Laboratories SA-製薬・医療分野:企業M&A・提携分析
    Summary Advanced Biological Laboratories SA (ABL) is a healthcare information technology company that provides integrated software solutions for personalised medicine. The company’s products include improving disease management software, project management software, cumulative reporting and related …
  • Turbo Power Systems Ltd:企業の戦略的SWOT分析
    Turbo Power Systems Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Point Resources AS:石油・ガス:M&Aディール及び事業提携情報
    Summary Point Resources AS (Point Resources) ,is engaged in developing, exploring and production of petroleum products. It explores and produces crude oil, gas and natural gas liquids (NGLs) through Ringhorne, Balder and Jotun fields. Point Resources also offers seismic surveys and drilling services …
  • Cellect Biotechnology Ltd (APOP):医療機器:M&Aディール及び事業提携情報
    Summary Cellect Biotechnology Ltd (Cellect Biotechnology) formerly Cellect Biomed Ltd is a clinical stage biotechnology company which develops stem cell selection technologies for the production of stem cells based products in the field of regenerative medicine. The company’s technology platform is …
  • RespireRx Pharmaceuticals Inc (RSPI):企業の財務・戦略的SWOT分析
    RespireRx Pharmaceuticals Inc (RSPI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Msig Holdings (Asia) Pte. Ltd.
    Msig Holdings (Asia) Pte. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Msig Holdings (Asia) Pte. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • CH2M HILL Companies, Ltd.:企業の戦略・SWOT・財務情報
    CH2M HILL Companies, Ltd. - Strategy, SWOT and Corporate Finance Report Summary CH2M HILL Companies, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Vocalink Limited
    Vocalink Limited - Strategy, SWOT and Corporate Finance Report Summary Vocalink Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Eversource Energy (ES):電力:M&Aディール及び事業提携情報
    Summary Eversource Energy (Eversource) is a utility holding company, which operates energy delivery business through its subsidiaries. It transmits and distributes electricity and natural gas. The company sources electricity from its facilities, long-term power supply agreements, and competitive ene …
  • Qualcomm Incorporated (QCOM):企業の財務・戦略的SWOT分析
    Qualcomm Incorporated (QCOM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆